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Abstract
This study was to determine the effectiveness (CD4 count and viral load) of a safe herbal concoction, α-Zam used 
by clients seeking herbal remedy for treatment of HIV infection in Nigeria.  51 patients taking α-Zam as complementary and 
alternative therapy through the herbal therapist were studied for a period of 16 months. Preliminary medical and
laboratory examinations using WHO and CDC criteria were done after confirmation of HIV infection by Western blotting in
the nearest teaching hospitals to the residence of the patients. Regular visits were paid to the patients after
commencement of the α-Zam to assess the side-effects, drug interactions, toxicity and effectiveness of the herbal remedy. 
There was a statistical significance (P<0.05) between pre-treatment and post-treatment CD4 count. 4 (7.8%) of the
patients had average increase in CD4 count of 262±16 cell/µL, 23 (45.1%) patients with average increase 310±16 cell/µL, 16
(31.4%) patients with average increase 456±25 cell/µL and 8 (15.7%) patients with average increase 510±36 cell/µL( %)
were at WHO staging I , II, III and IV respectively within 4 months on herbal therapy. There was very marked reduction in
viral (HIV-RNA) load with 41 (80.4%) and10 (19.6%) HIV infected patients had undetectable viral load and <1000 copies/ml
respectively after the therapy. All symptoms and signs associated with HIV infection in all patients fully subsided within 4
weeks of commencement of α-zam therapy and there was no evidence of negative drug interaction in those HIV patients 
using both the herbal and highly active anti-retroviral therapy (HAART). The study is in progress to determine periodic
immunological outcomes of post therapy in all patients.
Introduction
There are many herbal medicines used for human immunodeficiency virus (HIV) infection in many parts of the
world. Herbal remedies are herbs, herbal materials, herbal preparations and finished herbal products, that contain as
active ingredients parts of plants, or plant materials, or combinations thereof used to treat a multitude of ailments
throughout the world (WHO, 2002). It was estimated that about 80% of Africans used herbal remedies (WHO, 2002). The
nature and severity of the illness prompted many to seek for options outside orthodox medicines especially when they are
available in abundance. Herbal remedies may be used as complementary or alternative to orthodox medicines (King and
Homsy, 1997).
In 2006, 63% (about 2/3rd) of the people infected in the world live in sub-Saharan Africa, of which Nigeria has the
largest population (UNAIDS, 2006). Thus, Nigeria is the third country in the world with largest population of people
infected with HIV infection (WHO, 2005). Since the discovery of acquired immunodeficiency syndrome (AIDS) linked with
HIV as the causative agent in early 1980s, Nigeria was not excluded from the scourge of this dreadful infection (Gallo et al.,
1983). The use of herbal remedies for terminal illness is very common and the fact that HIV infection had no cure
prompted many to seek for traditional medicines and spiritual solutions.
Thus Nigerians living with HIV infection since 1987 when the first case was reported in the country resulted to
super-natural solutions (Abalaka, 2004). Despite the widely availability of non-expensive Highly Active Antiretroviral
therapy (HAART), many HIV patients in Nigeria are desperately looking for quicker solution to the existing problems of long
duration therapy by patronising herbal therapist. Campaigns by media houses and discouragement by medical
practitioners had not stopped the herbal therapists from flourishing in HIV infection treatment business.
The effectiveness of herbal remedies in HIV infection is not doubtful. There are many herbal remedies that have
been found to inhibit one or more steps in HIV replication (De Clereq, 2000; Kong et al 2003). Alkaloids derivatives herbal
remedies (e.g. Ancistrocladus korupensis) from tropical liana plant inhibit reverse transcriptase and HIV induced cell fusion
(Matthee et al., 1999). Pentosan poly-sulphate, a carbohydrate derivate inhibits HIV tat regulatory protein (p14) that
strongly activates transcription of proviral DNA (Watson et al., 1999). A coumarin herbal remedy in form of canolides from
tropical forest tree (Calophyllum lanigerum) was rated as non nucleoside reverse transcriptase inhibitor in potency
Onifade et al., Afr J Tradit Complement Altern Med. (2011) 8(1):37-44 38
Page38
(Dhamaratne et al., 2002). Despite the fact that sero-deconversion is very rare with HAART, some herbal remedies (e.g.
Chinese medicines) have been documented in serodeconversion of HIV infected patients (Lu, 1997).
However, many HIV patients taking herbal remedies denied when asked by medical practitioners (Dwyer et al.,
1995). The possible negative drug interaction between orthodox medicine and herb had been a major concern. St John’s
wort, herbal derived vitamins and garlic were documented to have caused negative drug interaction with anti-HIV drugs in
some HIV patients (Dhalla et al., 2006; Nyika, 2007). However, many herbal medicines decreased drug resistance
associated orthodox anti-retroviral drugs. Coumarins in combination therapy with nevirapine (component of HAART)
decreased resistance due to HIV mutation (Dharmaratne et al., 2002; Yu et al., 2003).
There are many herbal remedies that are effective against HIV infection in Nigeria (Elujoba, 2005). Many of these
documented herbal remedies act on the opportunistic infections caused by micro-organisms (Abere and Agoreyo, 2006;
Elujoba, 2005). Baissea axillaries Hua, a popular herbal remedy in Nigeria used to treat many diseases was also effective in
bacterial caused opportunistic infections in HIV patients (Abere and Agoreyo, 2006). However, neem leaves that are widely
distributed in Nigeria increased the CD4 count and general well being significantly in HIV patients (Mbah et al., 2007). Thus
there is a need to investigate the level of effectiveness of α-Zam, an herbal remedy used by many HIV patients in Nigeria in 
patients taking it as alternative or complementary therapy.
Materials and Methods
This study got ethical approval from Faculty of Health and Social Care Sciences of Kingston University and St
George’s University of London thus leading to ATAS clearance in United Kingdom. Osun State University, Osogbo and
Igbinedion University, Okada in Edo State also gave ethical approval to this study in Nigeria.
Α-Zam -Is a safe herbal concoction that contained saponins (titerpene glycosides), tannins, cardenolides, alkaloids and
possibly anthraquinones (Onifade et al., 2010). The adult table-spoon (about 10ml) of the concoction was diluted with
about 50ml of warm water. The dosage was reduced to 5ml for paediatric patient. Each freshly constituted diluted
medication was taken three times daily before food and normally for three months by patient at home (out-patient)
Patients were the HIV infected patients seeking herbal remedies as alternative or complementary therapy to
HAART at α-Zam therapist herbal centres.  
Herbal centre:Herbal therapist confidence was gained and consent sought for using his patients and herbal remedy for this
study. All the new patients coming for treatment on out-patient were recruited into the study after counselling and gaining
their consents. The herbal therapist recruits patient via well treated ‘former HIV patient’ and their relatives. The herbal
therapist dispensed a monthly α-Zam dosage in 1litre container for patient to come back for monitoring and review (out-
patient).Each patient’s contact and address was taken for monitoring, bi-monthly visits and repeat of medical and
laboratory examinations when necessary.
Patients’ selection: Power calculation was used to determine the sample size for this study. The pilot study was done. The
patients were selected based on HIV positive test result from the diagnosed orthodox hospitals (government and private)
however, only 51 patients that were confirmed (Western blot) at LAUTECH teaching hospital and Ahmadu Bello University
Teaching Hospital and completed their herbal therapy within 5 months between September 2008 and December 2009
were considered for this study.
Patients: Blood sample for HIV confirmatory test in Nigerian Government owned tertiary institution laboratory (LAUTECH
Teaching Hospital, Osogbo and Ahmadu Bello Teaching Hospital, Zaria) were done on all the patients in this study. All the
samples were sent for laboratory analysis in teaching hospitals on out-patient basis. The viral (HIV-RNA) load was done at
research centre via the LAUTECH teaching hospital while the CD4 count and other laboratory tests were done at both
teaching hospitals used for this study. The study conducted preliminary examinations (laboratory and medical) using World
Health Organisation (WHO, 2007) and Centre for Disease Control and Prevention (CDC, 1993) staging criteria and identified
associated opportunistic infections or systemic diseases. The patients taking HAART with α-Zam as complementary therapy 
were noted.
Medical examination: Skin, peripheral palpable lymph nodes, anaemia, body mass index, spleen, liver, kidney, chest, heart,
including radiological investigations to ascertain the level of involvement of the organs
Laboratory- Immunology: CD4/CD8 count, B cell, Electrophoresis, ELISA and Western blotting techniques to confirm HIV
infection.
Virology: viral (HIV-RNA) load using Polymerase Chain Reaction (PCR)
Haematology: Full Blood Count (FBC), blood film, Erythrocyte Sedimentation Rate (ESR)
Clinical chemistry: Electrolyte& Urea (E&U), Creatinine, Liver function test (LFT), C-reactive protein (CRP) and urinalysis.
Microbiology; blood microscopy, culture and sensitivity, sputum AAFB, urine microscopy and blood films for parasites
when there was evidenced of infection
Results
The results are presented in Tables 1-4 and Figures 1-4.
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Table 1:  showing the CD4 count and viral load of patients in WHO Staging I taking α-Zam 
Patient
no
Sex Age Pre-
treatment
CD4 count
(cell/µL)
Pre-treatment
HIV-RNA(viral
load)
copies/ml
Post-
treatment
CD4 count
(cell/µL)
Post-treatment
HIV-RNA(viral
load) copies/ml
A-zam
or
HAART
or both
Increase in
CD4 count
06/z F 30 400±31.3 11000±4000 700±50 undetectable A-zam 300±18.9
24/Z F 41 290±23.8 21000±1000 580±10 undetectable A-zam 290±13.9
17/OS F 29 280±28.8 31000±6000 540±30 undetectable A-zam 260±1.1
22/Z F 39 380±21.3 13000±3000 580±10 undetectable A-zam 200±31.1
Mean 1 34.75 337.5±27 19000±3500 600±25 262.2±16
Patients
<200
200-299
≥300
Figure 1: showing increase in CD4 count with the % of WHO staging I HIV patients
Patients
<200
200-299
≥300
Figure 2:  showing the increase inCD4 count with% of HIV patients in WHO staging II taking α-zam 
Onifade et al., Afr J Tradit Complement Altern Med. (2011) 8(1):37-44 40
Page40
There was statistical significant difference (P<0.05) between pre-treatment and post treatment CD4 count in all
the WHO staging groups of HIV patients using analysis of variance.
All the liver functions, electrolyte, urea and creatinine tests were normal during this study. All the haematological
and microbiological parameters indicating possible presence of opportunistic infections became normal within a month in
all patients in this study.
All the signs and symptoms associated with HIV infection presented by all patients in this study fully subsided within 3
weeks after commencement of the herbal concoction.
Table 2: showing the CD4 count and viral load of HIV patients in WHO Staging II taking α-Zam
Patient
no
Sex Age Pre-
treatment
CD4 count
(cells/µL)
Pre-
treatment
HIV-RNA
(viral load)
copies/ml
Post-
treatment
CD4 count
(cells/µL)
Post-treatment
HIV-RNA (viral
load) copies/ml
A-zam
or
HAART
or both
Increase in
CD4 count
05/z M 38 260±0.2 44,000±333
6
840±56 undetectable A-zam 580±56.2
10/Z F 44 320±12.3 35000±1460 800±47.7 undetectable A-zam 480±35.4
07/z F 30 280±4 42000±1251 750±37.3 undetectable A-zam 470±33.3
19/OS F 34 280±4 32000±834 740±35.2 undetectable A-zam 460±31.2
27/z F 39 260±0.2 41,000±271
0
670±20.6 undetectable A-zam 410±20.8
28/OS F 40 220±8.6 31000±625.
5
560±2.4 undetectable A-zam 340±6.2
26/OS F 42 220±8.6 29000±208.
5
550±4.4 undetectable A-zam 330±4.1
23/OS M 34 260±0.2 25000±625.
5
590±4.1 undetectable A-zam 330±4.1
18/z F 36 260±0.2 27000±208.
5
570±0.3 undetectable A-zam 310±0.1
16/OS F 32 230±6.5 35000±1459
.6
530±8.6 undetectable A-zam 300±2.2
15/OS F 41 270±1.9 29000±208.
5
560±2.4 undetectable both 290±4.2
25/OS M 46 250±2.3 27000±208.
5
540±6.5 undetectable A-zam 290±4.2
21/z M 41 280±4 22000±1251 570±0.3 undetectable both 290±4.2
28/z M 34 280±4 15000±2710 570±0.3 undetectable A-zam 290±4.2
19/z F 41 248±2.7 30000±417 530±8.6 undetectable A-zam 282±5.9
25/z M 37 230±6.5 31000±625.
5
490±17 <500 A-zam 260±10.5
20/OS F 26 270±1.9 33000±1042
.6
520±10.7 undetectable A-zam 250±12.6
27/z M 28 290±6 16000±2502 540±6.5 undetectable A-zam 250±12.6
23/z F 38 240±4.4 27000±208.
5
480±19.1 <500 A-zam 240±14.7
12/OS M 34 290±6.1 36000±1668 490±17 <500 A-zam 200±23
14/Z F 48 231±6.3 29000±208.
5
400±35.7 <500 both 169±29.5
07/OS M 35 235±5.4 29000±208.
5
400±35.7 <1000 A-zam 165±30.3
13/Z F 38 300±8.1 21000±1460 450±25.3 <500 A-zam 150±33.4
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Mean 2 37.2 261±4.5 28000±1387 571.3±17.5 variable 310.3±15.8
Table 3: showing the CD4 and viral load of HIV patients in Stage III taking α-Zam 
Patient
no
Sex Age Pre-
treatment
CD4
(cell/µL)
Pre-treatment
HIV-RNA(viral
load)
copies/ml
Post-
treatment
CD4
(cell/µL)
Post-treatment
HIV-RNA(viral
load) copies/ml
A-zam or
HAART
or
both
Increase in
CD4 count
03/Z M 10 240±1.7 46000±938 890±46.7 undetectable A-zam 650±48.4
05/OS F 32 270±5.9 35000±1813 890±46.7 undetectable A-zam 620±40.9
11/Z F 36 300±13.4 39000±813 890±46.7 undetectable A-zam 590±33.4
09/OS F 24 187±14.9 50000±1938 750±11.7 undetectable A-zam 563±26.6
02/OS F 23 320±18.4 34000±2063 880±44.2 undetectable A-zam 560±25.9
11/OS M 43 232±3.7 46000±938 750±11.7 undetectable A-zam 518±15.4
08/OS M 36 245±0.4 45000±688 740±9.2 undetectable A-zam 495±9.6
22/OS M 46 250±0.9 47000±1188 690±3.4 undetectable A-zam 440±4.1
15/Z F 35 220±6.7 49000±1688 650±13.4 undetectable A-zam 430±6.6
04/OS M 39 270±5.9 37000±1313 690±3.4 undetectable A-zam 420±9.1
13/OS M 38 340±23.4 33000±2313 730±6.7 undetectable A-zam 390±16.6
16/Z F 25 240±1.7 50000±1938 620±20.8 undetectable A-zam 380±19.1
03/OS M 45 200±11.7 38000±1063 560±35.9 undetectable A-zam 360±24.1
20/Z M 37 210±9.2 38000±1063 520±45.9 undetectable A-zam 310±36.6
14/OS F 21 190±14.2 54000±2938 490±26.7 <500 A-zam 300±39.1
02/z F 8 232±3.7 35000±1813 510±48.4 <500 A-zam 278±44.6
Mean 3 31.1 246.6±8.5 42250±1532 703.3±29 variable 456.5±25
Patients
<200
200-299
≥300
Figure 3: showing increase in CD4 count of HIV patients in WHO staging III taking α-Zam 
Table 4:  showing the CD4 count and viral load of HIV patients in Stage IV taking α-Zam 
Patient
no
Sex Age Pre-
treatment
CD4 count
(cell/µL
Pre-treatment
HIV-RNA(viral
load)
copies/ml
Post-
treatment
CD4 count
(cell/µL)
Post-treatment
HIV-RNA(viral
load) copies/ml
A-zam
or
HAART
or both
Increase in
CD4 count
12/z M 29 187±10.4 49000±574.5 820±53.9 undetectable both 633±30.8
01/OS M 25 137±7.3 52000±486.1 760±32.7 undetectable A-zam 623±40
01/z F 7 137±7.3 51000±132 760±32.7 undetectable A-zam 623±40
08/z M 46 140±6.2 53000±839.7 750±29.2 undetectable A-zam 610±35.4
04/Z M 28 192±12.2 50000±221 780±39.8 undetectable both 588±27.6
21/OS F 31 178±7.2 50000±221 570±34.5 undetectable A-zam 392±41.7
09/z M 42 140±6.2 51000±132.6 450±76.9 <500 A-zam 310±70.7
06/OS M 37 150±2.7 49000±574.5 450±76.9 <1000 both 300±74.2
Mean 4 30.6 157.6±7.4 50625±397.7 667.5±47 variable 509.9±36
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Patients
undetectable
<500copies/ml
<100copies/ml
Figure 4:  showing the summarised viral (HIV-RNA) load of all patients taking α-Zam 
Discussion
The role of herbal remedies in treatment of infections could not be over-emphasized. The herbal therapies are
widely used by HIV patients and many denied when asked by orthodox practitioners (Dwyer et al., 1995 and Liu et al.,
2009). In this study, 6 (11.8%) declared the concurrent use of HAART with α-Zam. Contrary to expectation of significant 
positive drug interaction, there was no sifnificant increase in CD4 count of all patients taking herbal concoction and HAART
(complementary therapy) in this study. Nyika (2007) concluded in his study that some herbal remedies negatively
interacted with orthodox anti-retroviral therapy but there was no noticeable harmful drug reaction in all patients taking
complementary therapy in this study.
HIV infection had no orthodox curative therapy propelled many infected patients to desperately seek for
alternative medicines. Thus any form of treatments was used to combat HIV infection. This manifested in this study with
more patients declaring the use of both α-zam and HAART at both clinical stages as seen in table II and IV.  The WHO 
staging II and IV patients sought active treatment to HIV infection because further reduction in immunity would be
dangerous to their health. However, the complementary therapy was more in patients at advanced HIV staging as seen in
table IV with 3 of 8 patients using both α-Zam and HAART. This result of this study supports the earlier studies that many 
HIV patients use complementary therapy (Liu et al., 2009).
There were more patients in clinical staging II (23 HIV patients) compared to other 3 stages in this study. The
clinical WHO staging II HIV patients represented the active interventional stage in HIV infection. The reduction in immunity
of HIV patients in at WHO staging II would make it easier for health practitioners, patients’ relatives and patients to sought
for full action to combat the deadly virus. The rapid disappearance of symptoms associated with HIV infection made many
HIV patients relax in medication adherence thus slow increase in immunity manifesting withCD4 count as seen in table II.
The increase in CD4 count of <300 cell/µL in some HIV patients over the period of this study could be due to less adherence
to medication by HIV patients. From figure II, 13 (56%) of 23 HIV patients had less than average 300 cell/µL (75 cells/µL per
month) increase inCD4 count unlike almost all patients in stage III and IV. This result was in support of earlier studies of HIV
patients’ poor adherence to anti-retroviral therapy (Duqqan et al., 2009; Minkoff et al., 2010; Talam et al., 2009).
A-zam, an herbal concoction significantly decreased the viral (HIV-RNA) load to undetectable level in many
patients in this study. Despite there was low increase in CD4 count in staging I patients, the herbal remedy effectively
reduced the HIV in blood circulation to undetectable level in 4 months on therapy. The low viraemia (19,000) accounted for
total reduction of HIV and total increase in CD4 count as seen in table and figure I. Tani et al. (2002) reported that herbal
remedies improved the quality of life paediatric infected patients with increase in CD4 count and decrease in viral load
over a period of 8years therapy, α-zam reduced viral (HIV-RNA) load to undetectable level in many patients in shorter 
period in this study.
Contrary to expectation and earlier studies that many HIV patients presented late or at advance state, less (24
patients) were seen in this study (Ajayi et al 2009). The advanced stage of HIV infection manifested in patients at WHO
staging III and IV with pre-treatment average CD4 count of 247 cell/µL and 158 cell/µL respectively. The high level of pre-
treatment viraemia (average 42,000 and 51000 copies/ml respectively) and low level of pre-treatment CD4 count (247 and
157 cells/µL) as seen table III and IV resulted to rapid high increase in CD4 after treatment (457 and 510 cell/µL
respectively). Although many patients (94% and 100% of stage III and IV respectively) with advanced level of terminal
infection would be expected to adhere to medication, all patients except one at stage III in this study had result that
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reflected adherence to herbal medication.  Thus α-zam effectiveness was affirmed by improved in clinical well beings of 
HIV patients at advanced stage.
UNAIDS/WHO (2005) estimated that many women in sub-Saharan were infected with HIV infection. There were
many women taking herbal concoction for HIV infection in this study. All the patients at stage I were women and 28 of 51
HIV patients in this study were female. This showed that many HIV infected female patients were infected with HIV
infection or sought for active HIV treatment at early stage (Adeleke et al., 2009). However, less women (2 of 6) patients
were using complementary therapy and few female patients presented at advanced stage of HIV infection (WHO staging
IV) in this study. Thus this study showed that many women infected with HIV infection used herbal remedies.
The effectiveness of herbal remedies led to their use in HIV infection as complementary or alternative in Nigeria.
A-zam effectively controls HIV infection irrespective of clinical stage of the patient. This herbal concoction increased the
CD4 count by average of 262, 310, 457 and 510 cells/ µL in WHO staging I, II, III, and IV patients respectively. The viral (HIV-
RNA) load drastically reduced from average of 19000 copies/ml to undetectable level in all patients in staging I and from
51000 copies/ml to <1000 copies /ml in stage IV HIV patients. The increase in CD4 count and decrease in viral load
manifested with disappearance of symptoms and signs associated with HIV infection. Thus α-zam herbal concoction has 
potent anti-HIV activities and could be developed for use like neem leaf and Baissea axillaries Hua products in HIV infection
in Nigeria (Abere and Agoreyo 2006; Mbah et al., 2007). The CD4 count and viral (HIV-RNA) load results of this study
supports earlier studies that some herbal remedies actively controlled HIV infection (Mills et al., 2005; Liu, 2007; Lu, 1997).
This study concluded that α-Zam (herbal concoction) is an effective anti-HIV agent by causing significant increase 
in CD4 counts and marked decrease in viral (HIV-RNA) load with no remarkable harmful drug interaction with HAART and
could be studied further for periodic immunologic and virologic post therapy in HIV patients taking it as alternative or
complementary therapy.
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